STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRDL
  4. [6-K] Cardiol Therapeutics Inc. Current Report (Foreign Issuer)

Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. reported the results of its 2026 Annual General Meeting of Shareholders, held virtually on June 24, 2026. Shareholders voted overwhelmingly in favour of all management resolutions.

All eight nominated directors were elected for the ensuing year, each receiving at least 96% of votes cast, and BDO Canada LLP was appointed as auditor for the next fiscal year with authority for directors to set their remuneration.

The filing also reiterates Cardiol’s focus on developing its lead small-molecule drug candidate CardiolRx™ for recurrent pericarditis and acute myocarditis, including a completed Phase II MAvERIC-Pilot study, an ongoing pivotal Phase III MAVERIC trial, and a completed Phase II ARCHER study, as well as its development of CRD-38 for inflammatory heart disease.

Positive

  • None.

Negative

  • None.
Votes for Dr. Timothy Garnett 29,855,359 shares Votes cast for election of director at 2026 AGM; 99.19% of votes cast
Votes for Jennifer Chao 28,965,662 shares Votes cast for election of director at 2026 AGM; 96.24% of votes cast
Votes for David Elsley 29,528,289 shares Votes cast for election of director at 2026 AGM; 98.11% of votes cast
Votes for Colin Stott 29,785,651 shares Votes cast for election of director at 2026 AGM; 98.96% of votes cast
Recurrent pericarditis Phase III trial Phase III MAVERIC Ongoing pivotal trial of CardiolRx™ in recurrent pericarditis (NCT06708299)
U.S. heart failure healthcare costs US$30 billion per year Associated healthcare costs in the United States for heart failure
Annual General Meeting of Shareholders financial
"announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually"
Orphan Drug Designation regulatory
"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Phase III MAVERIC trial medical
"the ongoing pivotal Phase III MAVERIC trial (NCT06708299)"
Phase II MAvERIC-Pilot study medical
"The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788)"
forward-looking information regulatory
"This news release contains "forward-looking information" within the meaning of applicable securities laws."
Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.
inflammasome pathway activation medical
"CardiolRx™ modulates inflammasome pathway activation, an intracellular process known to play an important role"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Cardiol Therapeutics (CRDL) shareholders approve at the 2026 AGM?
Shareholders overwhelmingly approved all management resolutions at the 2026 AGM, including electing eight directors and appointing BDO Canada LLP as auditor. Each director received at least 96% of votes cast, indicating strong support for the current board and governance structure.

Who was elected to the Cardiol Therapeutics (CRDL) board at the 2026 AGM?
Shareholders elected eight directors for the ensuing year: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos, and Colin Stott. Each nominee received between 96.24% and 99.19% of votes cast in favour.

Which auditor did Cardiol Therapeutics (CRDL) appoint for the next fiscal year?
Shareholders approved the appointment of BDO Canada LLP as auditor for the next fiscal year and authorized the board to fix their remuneration. This maintains an external audit relationship aimed at supporting the company’s financial reporting and regulatory compliance requirements.

What is Cardiol Therapeutics’ (CRDL) lead drug candidate CardiolRx™ targeting?
CardiolRx™ targets inflammatory and fibrotic processes in heart disease, including pericarditis, myocarditis, and heart failure. It modulates inflammasome pathway activation and is being evaluated in the completed Phase II MAvERIC-Pilot and ARCHER studies, and the ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis.

What clinical programs are underway or completed for CardiolRx™ at Cardiol Therapeutics (CRDL)?
The MAVERIC Program includes a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis. The ARCHER Program includes a completed Phase II study in acute myocarditis, assessing safety, tolerability, and efficacy in this patient population.

What is CRD-38 and how does it fit Cardiol Therapeutics’ (CRDL) pipeline?
CRD-38 is a novel, subcutaneously administered drug formulation being developed for inflammatory heart disease, including heart failure. Heart failure is a leading cause of death and hospitalization, with associated U.S. healthcare costs exceeding US$30 billion per year, underscoring the potential market need.

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

 

 

 
 

 

SUBMITTED HEREWITH

Exhibits

Exhibit   Description
     
99.1   News Release dated June 25, 2026 - Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
     
Date: June 25, 2026 By: /s/ Christopher Waddick
    Christopher Waddick
  Title: Chief Financial Officer

 

 

EXHIBIT 99.1

 

 

 

 

 

 

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO, June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated May 7, 2026.

Resolutions proposed and approved at the AGM were:

  • The election of the following directors for the ensuing year: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos, and Colin Stott.
  • The appointment of BDO Canada LLP as auditors of the Company for the next current fiscal year and the authorization of the Directors of the Company to fix the remuneration to be paid to the auditors.

The results of the voting on the election of Directors are as follows:

Nominees Number of Shares For Percentage of Votes Cast
Dr. Guillermo Torre-Amione 29,028,685 96.45 %
David Elsley 29,528,289 98.11 %
Chris Waddick 29,786,108 98.96 %
Teri Loxam 29,787,560 98.97 %
Dr. Timothy Garnett 29,855,359 99.19 %
Jennifer Chao 28,965,662 96.24 %
Peter Pekos 29,027,205 96.44 %
Colin Stott 29,785,651 98.96 %

A webcast of the AGM will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™ in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-reports-results-of-2026-annual-general-meeting-of-shareholders-302810079.html

SOURCE Cardiol Therapeutics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2026/25/c7422.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 25-JUN-26

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases